What is Anil Singal's NPI number?

Anil Singal's National Provider Identifier (NPI) is 1417154006, a unique 10-digit ID issued by CMS for use in standard healthcare transactions.

What is Anil Singal's specialty?

Anil Singal is listed in the NPPES registry with a primary specialty of Dermatology Physician (Allopathic & Osteopathic Physicians).

Where is Anil Singal located?

Anil Singal's practice location on file with NPPES is 420 N Main St Ste 600, Chelsea, MI 48118-1703.

What is Anil Singal's phone number?

The practice phone number listed in the NPPES registry for Anil Singal is (734) 385-7255.

Does Anil Singal accept Medicare?

Anil Singal is approved to bill Medicare according to CMS PECOS enrollment data (2026.04.01). Confirm current participation with the provider before scheduling.

Is Anil Singal's NPI active?

Yes — Anil Singal's NPI (1417154006) is active in the NPPES registry as of the last update on 2021-06-24.

IndividualActiveAccepts Medicare

Anil Singal, MD

NPI 1417154006 · Dermatology Physician · Chelsea, MI

Anil Singal, MD is a Dermatology Physician provider in Chelsea, MI (NPI 1417154006).

Provider details

NPI number: 1417154006
Entity type: Individual
Primary specialty: Dermatology PhysicianAllopathic & Osteopathic Physicians
Credential: MD
Sex: Male
Sole proprietor: No
License: 4301089566 (MI)

Practice location

420 N Main St Ste 600

Chelsea, MI 48118-1703

Phone: (734) 385-7255

Fax: (734) 274-4925

Street-level locationGet directions

More MI providers

Mailing address

420 N Main St Ste 600

Chelsea, MI 48118-1703

Specialties & taxonomies

Dermatology PhysicianPrimary207N00000XLicense 4301089566 (MI)
Allopathic & Osteopathic Physicians

Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)

Profile Score

Detailed profile(83/100 index)

A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.

Registry tenure25% of score
19 yrs in NPPES registry
Profile completeness25% of score
100% of core fields populated
Practice footprint15% of score
1 documented practice location
Medicare service volume (vs. specialty peers)25% of score
4,398 Medicare services, 2024 (ranked within specialty)
Open Payments transparency10% of score
Has Open Payments disclosures (2024)

Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.

What this provider does (Medicare)

Based on Medicare fee-for-service claims, 2024; not all care is captured.

Service (HCPCS)	Medicare services	Typical Medicare-allowed (2024)
Destruction of Precancer Skin Growth, 2-14 Growths17003	1,810	$6
Destruction of Precancer Skin Growth, 1 Growth17000	580	$52
Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213	481	$91
Biopsy of Related Skin Growth, First Growth11102	379	$95
Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214	366	$127
Biopsy of Related Skin Growth, Each Additional Growth

What this provider prescribes (Medicare Part D)

Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.

Drug	Part D claims (2024)	Beneficiaries
Triamcinolone Acetonide	303	231
Ketoconazole	208	114
Clobetasol Propionate	158	103
Methotrexate Sodiumbrand: Methotrexate	106	15
Betamethasone Dipropionate	77	46
Doxycycline Hyclate	76	42
Metronidazole	70	52
Hydroxychloroquine Sulfate

Transparency — industry payments

Based on CMS Open Payments, 2024; not all care is captured.

$392 across 18 records (Open Payments 2024)

Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.

Enumerated: 2007-06-28
Last updated: 2021-06-24
Certified: 2021-06-24

Frequently asked questions

What is Anil Singal's NPI number?: Anil Singal's National Provider Identifier (NPI) is 1417154006, a unique 10-digit ID issued by CMS for use in standard healthcare transactions.
What is Anil Singal's specialty?: Anil Singal is listed in the NPPES registry with a primary specialty of Dermatology Physician (Allopathic & Osteopathic Physicians).
Where is Anil Singal located?: Anil Singal's practice location on file with NPPES is 420 N Main St Ste 600, Chelsea, MI 48118-1703.
What is Anil Singal's phone number?: The practice phone number listed in the NPPES registry for Anil Singal is (734) 385-7255.
Does Anil Singal accept Medicare?: Anil Singal is approved to bill Medicare according to CMS PECOS enrollment data (2026.04.01). Confirm current participation with the provider before scheduling.
Is Anil Singal's NPI active?: Yes — Anil Singal's NPI (1417154006) is active in the NPPES registry as of the last update on 2021-06-24.

Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.

What this provider does (Medicare)

Based on Medicare fee-for-service claims, 2024; not all care is captured.

Service (HCPCS)	Medicare services	Typical Medicare-allowed (2024)
Destruction of Precancer Skin Growth, 2-14 Growths17003	1,810	$6
Destruction of Precancer Skin Growth, 1 Growth17000	580	$52
Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213	481	$91
Biopsy of Related Skin Growth, First Growth11102	379	$95
Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214	366	$127
Biopsy of Related Skin Growth, Each Additional Growth

What this provider prescribes (Medicare Part D)

Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.

Drug	Part D claims (2024)	Beneficiaries
Triamcinolone Acetonide	303	231
Ketoconazole	208	114
Clobetasol Propionate	158	103
Methotrexate Sodiumbrand: Methotrexate	106	15
Betamethasone Dipropionate	77	46
Doxycycline Hyclate	76	42
Metronidazole	70	52
Hydroxychloroquine Sulfate

Transparency — industry payments

Based on CMS Open Payments, 2024; not all care is captured.

$392 across 18 records (Open Payments 2024)

Provider details

Practice location

Mailing address

Specialties & taxonomies

Profile Score

What this provider does (Medicare)

What this provider prescribes (Medicare Part D)

Transparency — industry payments

Registry dates

Frequently asked questions

Specialties & taxonomies

Frequently asked questions

Profile Score

What this provider does (Medicare)

What this provider prescribes (Medicare Part D)

Transparency — industry payments